WO2025079025 - IDES-RAPAMYCIN CONJUGATE IN AAV GENE THERAPY

National phase entry is expected:
Publication Number WO/2025/079025
Publication Date 17.04.2025
International Application No. PCT/IB2024/059972
International Filing Date 11.10.2024
Title [English] IDES-RAPAMYCIN CONJUGATE IN AAV GENE THERAPY [French] CONJUGUÉ IDES-RAPAMYCINE DANS UNE THÉRAPIE GÉNIQUE AAV
Applicants ** TAKEDA PHARMACEUTICAL COMPANY LIMITED 1-1, Doshomachi 4-chome Chuo-ku Osaka-shi, Osaka 541-0045, JP
Inventors ** KHAN, Tayeba c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US KENNISTON, Jon A. c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US NATARAJAN, Madhusudan c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US PALLISER, Deborah c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US LEE, Hong Myung c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US RICE, Elise c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US WATTERS, Alexander L. c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US PAPAIOANNOU, Nikolaos c/o Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139, US
Priority Data 63/590,195  13.10.2023  US
front page image
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 3154
EPO Filing, Examination 28912
Japan Filing 567
South Korea Filing 577
USA Filing, Examination 11885
+ Add country
MasterCard Visa
Total: 45095
QUOTE TO EMAIL ONLINE QUOTE
Abstract [English] ., rapamycin, for immunosuppression in applications such as gene therapy. The present disclosure also provides methods of synthesis of conjugates and methods of conjugation (i.e. sortase-mediated conjugation) of payloads to IdeS or IdeZ for use in such applications. [French] La présente invention concerne également des procédés de synthèse de conjugués et des procédés de conjugaison (c'est-à-dire de conjugaison à médiation par sortase) de charges utiles à IdeS ou IdeZ à utiliser dans de telles applications.